Skip to Main Content

Paper Details

Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Pediatric Blood and Cancer
5
2022
B, B-ALL, B-cell precursor acute lymphoblastic leukemia, CD19, CD3, Children, HC3, M2, MRD, Patients, blasts, blinatumomab, children, patients
Author NameAffiliation
Cornelia EckertCharite-Universitatsmedizin Berlin
  • 1 - 1

Datasets

Release 1.2